EUFLEXXA—the highest molecular weight of any linear HA, successfully binds to CD44 receptors2-11

Through its successful binding that provides physiologic effects, dual-acting EUFLEXXA treats OA knee pain IN TWO WAYS.2-4

Mechanical2-4

  • Improves viscoelasticity
  • Joint lubrication
  • Cushioning

Physiologic2-5

  • Disrupts the inflammatory cascade
  • Reduces pain
  • Protects cartilage
  • Stimulates endogenous HA production
The molecular STRUCTURE and weight of EUFLEXXA help it stand out 2,7-17

EUFLEXXA most closely resembles healthy, human HA2,6-11

This table does not represent all HA products.

Only HA products above a certain market share represented here.1

Durolane, a cross-linked HA, does not report their molecular weight.13

Gel-One, a cross-linked HA, does not report their molecular weight.15

*Same grade and specification of HA that is used in Orthovisc.2-4

ORTHOVISC and MONOVISC are registered trademarks of Anika Therapeutics, Inc. Gelsyn-3 and DUROLANE are trademarks of Bioventus LLC. Synvisc and Synvisc-One are trademarks of Genzyme Corporation. HYALGAN is a registered trademark of Fidia Farmaceutici S.p.A. SUPARTZ, SUPARTZ FX, and Gel-One are trademarks

of Seikagaku Corp.

The information set forth herein is presented to provide reference to various characteristics that were examined for the products in the HA class for treatment of OA knee pain. This information does not suggest or imply in any manner that any of the characteristics of each HA product, alone or in combination, are superior over another. Nor is it intended to imply that the products mentioned have comparable safety or efficacy, as head-to-head clinical data are not available for all.

Resources
& Coverage

Find helpful resources and coverage to
support your practice and your patients.

Get Support

Safety

Explore the demonstrated
safety profile of EUFLEXXA.

Discover the safety profile
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
  2. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
  3. Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Cartilage. 2019;10(1):43-52.
  4. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism
    of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disor. 2015;16:321.
  5. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.
  6. Nicholls M, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35:523-530.
  7. Orthovisc [package insert]. Woburn, MA: Anika Therapeutics, Inc; 2005.
  8. Supartz [package insert]. Durham, NC: Bioventus LLC; 2012.
  9. Gelsyn-3 [package insert]. Durham, NC: Bioventus LLC; 2016.
  10. Hyalgan [package insert]. Parsippany, NJ: Fidia Pharma USA Inc; 2011.
  11. Genvisc-850 [package insert]. Doylestown, PA: OrthogenRx; 2016.
  12. Supartz FX [package insert]. Durham, NC: Bioventus LLC; 2015.
  13. Durolane [package insert]. Durham, NC: Bioventus LLC.
  14. Monovisc. Summary of safety and effectiveness data. Monovisc Injectable Intra-articular Device-P090031.
  15. Gel-One [package insert]. Warsaw, IN.
  16. Synvisc [package insert]. Cambridge, MA: Genzyme Corp; 2010.
  17. Synvisc-One [package insert]. Cambridge, MA; Genzyme Corp; 2010.

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

©2024 Ferring B.V. All rights reserved.
US-EU-2300033

You have selected to go to the
healthcare professional website.

Are you a US healthcare professional?

Yes No

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.

Ok Cancel